<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="4880">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01918202</url>
  </required_header>
  <id_info>
    <org_study_id>A8241017</org_study_id>
    <nct_id>NCT01918202</nct_id>
  </id_info>
  <brief_title>A Study To Evaluate The PDE10 Enzyme Occupancy Following A Single Dose Of PF-02545920 In Healthy Male Volunteers</brief_title>
  <acronym>PET</acronym>
  <official_title>A Phase 1, Open-Label Adaptive Design Study To Evaluate PDE10 Enzyme Occupancy As Measured By Positron Emission Tomography (PET) Following Single Oral Dose Administration Of PF-02545920 In Healthy Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This Phase 1 study will evaluate PDE10 enzyme occupancy using Positron Emission Tomography
      after a single dose of PF-02545920 in Healthy male volunteers.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2014</start_date>
  <completion_date type="Anticipated">August 2014</completion_date>
  <primary_completion_date type="Anticipated">August 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science</study_design>
  <primary_outcome>
    <measure>Central PDE10A enzyme occupancy values in the striatum.</measure>
    <time_frame>Day 10</time_frame>
    <safety_issue>No</safety_issue>
    <description>Using Positron Emission Tomography and a radiotracer (MNI-659) for PF-02545920, the central PDE10A enzyme occupancy values will be measured in the striatum at different single oral doses of PF-02545920.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Central PDE10A enzyme occupancy values in the globus pallidus, in the caudate and in the putamen (separately).</measure>
    <time_frame>Day 10</time_frame>
    <safety_issue>No</safety_issue>
    <description>Using Positron Emission Tomography and a radiotracer (MNI-659) for PF-02545920, central PDE10A enzyme occupancy values in the globus pallidus, in the caudate and in the putamen be measured (separately) at different single oral doses of PF-02545920.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Observed Plasma Concentration (Cmax)</measure>
    <time_frame>Day 10</time_frame>
    <safety_issue>No</safety_issue>
    <description>Cmax for serum PF-02545920 during the post-dose positron emission tomography (PET) scan.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Reach Maximum Observed Plasma Concentration (Tmax)</measure>
    <time_frame>Day 10</time_frame>
    <safety_issue>No</safety_issue>
    <description>Tmax for serum PF-02545920 during the post-dose positron emission tomography (PET) scan.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average serum concentration</measure>
    <time_frame>Day 10</time_frame>
    <safety_issue>No</safety_issue>
    <description>Average serum 02545920 during the post-dose positron emission tomography (PET) scan.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Cohort 1 - 20 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort will include 4 HVs/completers who will receive a single 20 mg dose of PF-02545920.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2 ( adaptive dose, optional)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort 2 will include 4 HVs/completers who will receive a single dose of PF-02545920. The dose will be selected based on the results obtained for Cohort 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3 ( adaptive dose, optional)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort 3 will include 4 HVs/completers who will receive a single dose of PF-02545920. The dose will be selected based on the results obtained for Cohort 1.
Dose options range from 30 mg to 10 mg, 5 mg, 2mg, 1 mg. This cohort is optional</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>20 mg PF-02545920</intervention_name>
    <description>Subject will receive a single dose of 20 mg PF-02545920.</description>
    <arm_group_label>Cohort 1 - 20 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-02545920</intervention_name>
    <description>The dose will be selected based on the results obtained for Cohort 1. Dose options range from 30 mg to 10 mg, 5 mg, 2mg, 1 mg.
This cohort is optional.</description>
    <arm_group_label>Cohort 2 ( adaptive dose, optional)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-02545920</intervention_name>
    <description>The dose will be selected based on the results obtained for Cohort 1 and cohort 2.</description>
    <arm_group_label>Cohort 3 ( adaptive dose, optional)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  healthy male volunteers

        Exclusion Criteria:

          -  History of orthostatic hypotension

          -  History of prior radiation exposure for research purposes, or radiation therapy
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <phone>1-800-718-1021</phone>
  </overall_contact>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Huddinge</city>
        <state>Stockholm</state>
        <zip>SE- 141 86</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A8241017&amp;StudyName=A%20Study%20To%20Evaluate%20The%20PDE10%20Enzyme%20Occupancy%20Following%20A%20Single%20Dose%20Of%20PF-02545920%20In%20Healthy%20Male%20Volunteers</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 13, 2014</lastchanged_date>
  <firstreceived_date>August 5, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Enzyme occupancy</keyword>
  <keyword>PET</keyword>
  <keyword>Phosphodiesterase 10 inhibitor</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
